Long-term survival and prognostic factors of five-year survivors with complete resection of non–small cell lung carcinoma  by Okada, Morihito et al.
Long-term survival and prognostic factors of five-year
survivors with complete resection of non–small cell lung
carcinoma
Morihito Okada, MD, PhD
Wataru Nishio, MD, PhD
Toshihiko Sakamoto, MD, PhD
Hiroaki Harada, MD
Kazuya Uchino, MD
Noriaki Tsubota, MD, PhD
Objective: We analyzed the long-term follow-up data on cancer-
related death in 5-year survivors of complete resection of their
non–small cell lung cancer and examined the prognostic factors
having an impact on subsequent survival.
Methods: Of 848 consecutive patients with proven primary non–
small cell carcinoma who underwent complete removal of the
primary tumor together with hilar and mediastinal lymph nodes,
421 patients (49.6%) survived 5 years or longer after the initial
surgical treatment. Of all the data analyzed, only death related to
cancer was treated as death.
Results: The median follow-up of 5-year survivors was 84 months
from the original treatment (range, 60 to 200 months). Their overall
survival rate at 10 years was 91.0%. Multivariable Cox analysis
demonstrated that although advanced surgical-pathological stage (P
 .0001), nodal involvement (P  .0245), male gender (P  .0313), and non–
squamous type of the tumor (P  .0034) were significant, independent, unfavorable
prognostic determinants in all patients, none of the variables investigated signifi-
cantly influenced the long-term survival of 5-year survivors. The rate of recurrence
beyond 5 years was much lower compared with that within 5 years. In contrast, the
rate of occurrence of new malignancies was unchanged throughout the long-term
postoperative period.
Conclusions: Among 5-year survivors of complete resection of non–small cell lung
cancer, neither stage, nodal status, sex, nor histologic condition further affected
subsequent survival, suggesting that the 5-year interval might be sufficient to
declare that a patient with lung cancer has been cured.
Although pulmonary resection remains the most effective treatmentfor patients with non–small cell lung cancer who are presumed tohave no distant metastases and no lymph node involvement be-yond the resected specimen, a considerable number of thesepatients have recurrent lung cancer within 5 years. Generally, thesuccess or failure of therapeutic intervention including surgery in
patients with cancer has been assessed in time of survival, often with emphasis on
the first 5 years subsequent to the intervention. Despite our expectation of long-term
survival after complete resection of non–small cell lung cancer, recurrence can
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develop in one fourth of the patients, even of those with
stage IA disease.1-3 Therapeutic success can be overesti-
mated by survival rates restricted to the initial 5 years if the
risk of recurrence 5 years or later is substantial.4,5 There are
many articles regarding the natural history of patients with
resected non–small cell lung cancer during the early post-
operative period but few about the long-term survival of
such patients, in particular beyond 5 years. The purposes of
this study were to analyze the long-term follow-up data on
cancer-related death in patients after complete resection of
non–small cell lung cancer and to determine the significant
prognostic factors in patients alive 5 years from surgical
treatment of their initial cancer.
Patients and Methods
Between July 1984 and July 1997, 1060 consecutive patients were
operated on for primary lung cancer by the same surgical team. Of
the 1060 patients, 1031 patients were histologically diagnosed as
having non–small cell carcinoma, and 183 patients could not
undergo complete resection nor nodal dissection. During that pe-
riod, 848 patients with proven non–small cell carcinoma under-
went complete removal of the primary tumor together with ipsi-
lateral hilar and mediastinal lymph nodes. Of them, 421 patients
(49.6%) survived 5 years or longer. Patients who had evidence of
residual tumor at the surgical margin, malignant effusion, or N3
disease verified by intraoperative findings or postoperative patho-
logic examination were defined as having been subjected to an
incomplete surgery and were excluded from this study. The fol-
lowing criteria, based on and modified from those of Martini and
Melamed,6 have been used for the designation of multiple primary
lung cancers7: the tumors were anatomically separate, and the
tumors were histologically different. If the tumors were histolog-
ically the same, they must have no systemic metastases or medi-
astinal spread. In case of metachronous tumors with the same
histology, tumor-free interval should be at least 2 years. Tumors
with minute satellite nodules that were found incidentally within
the same lobe of the resected specimen were not excluded from
this study, because we were not certain whether these lesions
should be considered local tumor spread or not. Tumors with
satellite lesions in another lobe were excluded. Patients whose
tumors were subsequently classified as small cell carcinoma or
low-grade malignant tumor were also excluded. Surgical-patho-
logic staging was carried out according to the New International
Staging System for Lung Cancer.8
Routine systematic dissection of all the hilar and mediastinal
nodes was performed in every case, even if the preoperative
evaluation was N0 or N1.9 Every node dissected was examined by
pathologists to be diagnosed as microscopically positive or nega-
tive during and after the operation. No adjuvant therapies were
provided before or after surgery.
After surgery, the patients were examined at 3-month intervals
for 5 years and thereafter at 1-year intervals in general. The
evaluations included physical examination, chest roentgenogra-
phy, and tumor markers. Moreover, chest, abdominal, and brain
computed tomographic scans and a bone scintiscan were carried
out each year. Whenever any symptoms or signs of recurrence
appeared in these examinations, further evaluations to detect the
disease were performed.
Survival was calculated by the Kaplan-Meier method, and
differences in survival were determined by the log-rank analysis. A
multivariable analysis of several independent prognostic factors
was carried out using Cox’s proportional hazards regression
model. Zero time was the date of pulmonary resection, and the
terminal event was death attributable to cancer. To avoid contro-
versy, we defined death as a cancer-related death when recurrence
was evident before death or at autopsy. All other deaths by
noncancer or unknown causes were treated as withdrawals, which
means that death that was not caused by cancer was considered
censored. Significance was defined as P  .05.
TABLE 1. Histologic type
Cell type Number (%)
Adenocarcinoma 245 (58.2)
Squamous cell carcinoma 160 (38.0)
Adenosquamous carcinoma 8 (1.9)
Large cell carcinoma 8 (1.9)
Total 421 (100)
TABLE 2. Extent of pulmonary resection
Procedure Number (%)
Lobectomy
Lobe only 295 (70.1)
 Sleeve 36 (8.6)
Segmentectomy
Segment only 62 (14.7)
 Sleeve 4 (1.0)
Pneumonectomy
Unilateral lung 13 (3.1)
 Sleeve 1 (0.2)
Wedge resection 10 (2.4)
Total 421 (100)
TABLE 3. Surgical-pathological staging
Stage
Number (%)
All patients
5-year
survivors
IA T1 N0 285 (33.6) 181 (43.0)
IB T2 N0 200 (23.6) 109 (25.9)
IIA T1 N1 36 (4.2) 25 (5.9)
IIB T2 N1 64 (7.5) 25 (5.9)
T3 N0 45 (5.3) 22 (5.2)
IIIA T3 N1 26 (3.1) 7 (1.7)
T1 N2 33 (3.9) 16 (3.8)
T2 N2 73 (8.6) 11 (2.6)
T3 N2 36 (4.2) 5 (1.2)
IIIB T4 N0 16 (1.9) 11 (2.6)
T4 N1 15 (1.8) 7 (1.7)
T4 N2 19 (2.2) 2 (0.5)
Total 848 (100) 421 (100)
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Results
There were 291 men and 130 women with a mean age of
62.8 years (range, 30 to 82 years). Overall follow-up ranged
from 60 to 200 months, with a median of 84 months. The
histologic classification was adenocarcinoma in 58.2% of
the patients, squamous cell carcinoma in 38.0%, adenosqua-
mous carcinoma in 1.9%, and large cell carcinoma in 1.9%
(Table 1). Lobectomy was by far the most common proce-
dure and was performed in 331 patients (78.7%), including
36 combined sleeve resections of bronchi. Sixty-six seg-
mentectomies (4 bronchoplasties and 14 pneumonectomies
including 1 sleeve technique for the tracheobronchus) were
carried out (Table 2). As we followed the policy that lung-
saving procedures must always be kept in mind,10,11 the
ratio of bronchoplasties performed was relatively high
(9.8%), and that of pneumonectomies was very low. On the
basis of the international staging system, 68.9% of 5-year
survivors had stage I disease, 17.0% had stage II disease,
and 14.1% had stage III disease, although among all patients
subjected to complete resection, 57.2% had stage I disease,
17.0% had stage II disease, and 25.8% had stage III disease
(Table 3).
Multivariable Cox analysis of all patients (n  848)
subjected to complete resection for non–small cell lung
cancer demonstrated that surgical-pathological stage, nodal
involvement, sex, and histologic type of the tumor were
significant prognostic determinants (Table 4). However,
multivariable analysis of patients who were alive 5 years
after surgery showed that none of the variables examined
significantly influenced additional survival (Table 5). The
overall survival of the patients who had survived 5 years
postoperatively was 91.0% at 10 years (Figure 1). The
possibilities for patients who were alive 5 years after com-
plete resection of lung cancer to survive beyond 5 years
were excellent irrespective of the surgical-pathological
stage (Figure 2) or the nodal status (Figure 3), although
patients with a more advanced stage or nodal status tended
to have worse prognosis.
It is interesting to note that the long-term prognosis of
5-year survivors with non–squamous cell carcinoma was
worse (not significantly, P  .0574) than that of 5-year
survivors with squamous cell carcinoma (Figure 4). The
histopathologic difference in survival might suggest that in
some cases adenocarcinoma could progress slowly and re-
sult in recurrence beyond 5 years after complete removal of
the tumor. Moreover, although the rate of late recurrence
was much lower in patients alive for 5 years postopera-
tively, the occurrence rate for new malignancies remained
unchanged throughout the long-term follow-up period (Fig-
ure 5).
Discussion
One of the most important findings in this study was that
advanced stage, high involvement of lymph nodes, male
gender, and non–squamous cancer were independent, unfa-
vorable prognostic factors in all patients, but in 5-year
survivors, neither stage, nodal status, gender, nor histologic
condition further affected the subsequent survival, indicat-
ing that once the patients with complete resection of non–
small cell lung cancer survive beyond 5 years, there is no
TABLE 4. Multivariable analysis of prognostic factors among patients after complete resection of non-small cell lung
cancer (n  848)
Factors Unfavorable Favorable Risk ratio 95% CI P value
pN N1  N2 N0 1.570 1.060–2.326 .0245
p-stage II  III I 2.627 1.745–3.954 .0001
Age 65 65 1.222 0.966–1.545 .0952
Sex Male Female 1.379 1.029–1.848 .0313
Histologic type Non-SQ SQ 1.455 1.132–1.869 .0034
Extent of procedure Pn  Lo Se  We 1.225 0.836–1.795 .2977
CI, Confidence interval; SQ, squamous cell carcinoma; Pn, pneumonectomy; Lo, lobectomy; Se, segmentectomy; We, wedge resection.
TABLE 5. Multivariable analysis of prognostic factors among patients alive 5 years after complete resection of non-small
cell lung cancer (n  421)
Factors Unfavorable Favorable Risk ratio 95% CI P value
pN N1  N2 N0 1.421 0.344–5.865 .6275
p-stage II  III I 2.949 0.806–10.784 .1021
Age 65 65 1.441 0.575–3.615 .4357
Sex Female Male 1.469 0.569–3.791 .4269
Histologic type Non-SQ SQ 2.910 0.908–9.326 .0722
Extent of procedure Pn  Lo Se  We 1.141 0.253–5.151 .8637
CI, Confidence interval; SQ, squamous cell carcinoma; Pn, pneumonectomy; Lo, lobectomy; Se, segmentectomy; We, wedge resection.
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difference in survival concerning their clinicopathologic
factors (that is, the disease behaves the same after 5 years).
It must be emphasized that there were so few cancer-related
deaths beyond 5 years that it is possible that the test used for
statistic analysis was underpowered. It is of great interest to
note that although female patients had a significantly better
prognosis than male patients after surgery, 5-year female
survivors had a relatively worse prognosis beyond 5 years,
suggesting that in some female patients adenocarcinoma
might tend to progress slowly and to recur late after surgery.
There are some cases in which we can completely resect
a tumor with involvement of the mediastinal nodes (N2) or
direct extension into the adjacent structures (T3 to 4). In this
study, 34 patients with N2 disease (T1 to 4) and 20 patients
with T4 tumor were alive at 5 years from their initial
surgical treatment. In the present review, we found an
interesting case in which recurrence developed 6 years after
resection of a T2 N2 M0 squamous cell carcinoma and was
completely removed by surgery. The patient is still alive,
although 9 years have passed since the second surgery.
Despite presumed effective surgical treatment that is
considered best for locally located non–small cell lung
cancer, we are faced with failure to control the cancer
because of distant metastases, more so in the case of patients
with more advanced stage disease. Nevertheless, the pa-
tients who remain alive by 5 years after surgery appear to
have a favorable outlook because 91% of these patients do
not die of lung cancer thereafter. There is considerable
controversy regarding when we can consider a patient with
non–small cell lung cancer to have been cured. The Lung
Cancer Study Group emphasized the need for continued
surveillance for the survivors at 5 years after surgery be-
cause second primary cancers might recur after 5 years.5,12
In this study, the frequency of local pulmonary recurrence
after 5 years was 3%, and that of distant metastases was 6%.
Figure 1. Cumulative survival curves of patients alive 5 years
after complete resection of non–small cell lung cancer.
Figure 2. Cumulative survival curves of patients alive 5 years
after complete resection of non–small cell lung cancer according
to surgical-pathological stage.
Figure 3. Cumulative survival curves of patients alive 5 years
after complete resection of non–small cell lung cancer according
to involvement of lymph nodes.
Figure 4. Cumulative survival curves of patients alive 5 years
after complete resection of non–small cell lung cancer according
to histologic type of the tumor.
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Although second primary cancers for which incidence re-
mained unchanged throughout the long follow-up period
continued to pose a threat, the recurrence rate decreased
with time. Beyond 5 years, the low incidence of recurrence
as well as survival data unrelated to the stage determined at
the initial surgery are important, suggesting the 5-year in-
terval is sufficient to declare that a patient with lung cancer
has been cured.
References
1. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity
on survival after surgical resection in patients with stage I non-small
cell lung cancer. J Thorac Cardiovasc Surg. 2002;123:280-7.
2. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and
second primary tumors in resected stage I lung cancer. J Thorac
Cardiovasc Surg. 1995;109:120-9.
3. Martini N, Rusch VW, Bains MS, et al. Factors influencing ten-year
survival in resected stages I to IIIa non-small cell lung cancer. J Tho-
rac Cardiovasc Surg. 1999;117:32-6.
4. Okada M, Yoshikawa K, Hatta T, Tsubota N. Is segmentectomy with
lymph node assessment an alternative to lobectomy for non-small cell
lung cancer of 2 cm or smaller? Ann Thorac Surg. 2001;71:956-60.
5. Thomas PA Jr, Rubinstein L. Malignant disease appearing late after
operation for T1 N0 non-small-cell lung cancer. The Lung Cancer
Study Group. J Thorac Cardiovasc Surg. 1993;106:1053-8.
6. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac
Cardiovasc Surg. 1975;70:606-12.
7. Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Operative approach
for multiple primary lung carcinomas. J Thorac Cardiovasc Surg.
1998;115:836-40.
8. Mountain CF. Revisions in the International System for Staging Lung
Cancer. Chest. 1997;111:1710-7.
9. Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Proposal for
reasonable mediastinal lymphadenectomy in bronchogenic carcino-
mas: role of subcarinal nodes in selective dissection. J Thorac Car-
diovasc Surg. 1998;116:949-53.
10. Okada M, Tsubota N, Yoshimura M, et al. Extended sleeve lobectomy
for lung cancer: the avoidance of pneumonectomy. J Thorac Cardio-
vasc Surg. 1999;118:710-3.
11. Okada M, Yamagishi H, Satake S, et al. Survival related to lymph node
involvement in lung cancer after sleeve lobectomy compared with
pneumonectomy. J Thorac Cardiovasc Surg. 2000;119:814-9.
12. Thomas P, Rubinstein L. Cancer recurrence after resection: T1 N0
non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac
Surg. 1990;49:242-6.
Figure 5. Comparison of rates of recurrences and new malignan-
cies between patients who died of cancer within 5 years and
those alive 5 years after complete resection of non–small cell
lung cancer. Rates of occurrence were calculated as occur-
rences/eligible patient-year.
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